Douve, we will have data, hopefully from both SCIB1 Trial and MOD1 Trial, and as per todays from SCLP in Vulpes words we have their long term support, for all the reasons we have given, here on this BB.
Just perhaps we feel the data will support a far bigger commercial deal than a pre-clinical one, and the market seems to like it too.
As per RNS................."".Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time.""
So yes as you say................."". Did you notice that Vulpes have a Chief Risk Officer? He must have been busy recently""...........................and we passed!!!
As per RNS................."".Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time.""
So yes as you say................."". Did you notice that Vulpes have a Chief Risk Officer? He must have been busy recently""...........................and we passed!!!
Russellcox, a serious allegation, one I am prepared to put my name too, and have suggested for more than two years now...Couldn"t help but see year 1970s post dissing Scancell again, he hasn"t got a clue, take a look at their fundraise and hope Uncanny stops saying VAL should be valued in the same way. Seperate shares, different stratagies and platforms, but they have a regard for "second hand shareholders"" IMHO